JP6777652B2 - 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物 - Google Patents

炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物 Download PDF

Info

Publication number
JP6777652B2
JP6777652B2 JP2017555303A JP2017555303A JP6777652B2 JP 6777652 B2 JP6777652 B2 JP 6777652B2 JP 2017555303 A JP2017555303 A JP 2017555303A JP 2017555303 A JP2017555303 A JP 2017555303A JP 6777652 B2 JP6777652 B2 JP 6777652B2
Authority
JP
Japan
Prior art keywords
compound
independently selected
dihydrobenzo
methyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017555303A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018513180A5 (https=
JP2018513180A (ja
Inventor
ジェアンネ マリエ メネト クリステル
ジェアンネ マリエ メネト クリステル
ジョージズ ピエール‐オリヴィエ ドヨン ジュリアン
ジョージズ ピエール‐オリヴィエ ドヨン ジュリアン
イザベル ロジャー クラース ピーター
イザベル ロジャー クラース ピーター
アラールト ブリジット
アラールト ブリジット
マリア ポール ド ヴァシュテール マキシム
マリア ポール ド ヴァシュテール マキシム
アレッサンドロ トリカーリコ ジョバンニ
アレッサンドロ トリカーリコ ジョバンニ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of JP2018513180A publication Critical patent/JP2018513180A/ja
Publication of JP2018513180A5 publication Critical patent/JP2018513180A5/ja
Application granted granted Critical
Publication of JP6777652B2 publication Critical patent/JP6777652B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017555303A 2015-04-23 2016-04-19 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物 Active JP6777652B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1506894.3 2015-04-23
GBGB1506894.3A GB201506894D0 (en) 2015-04-23 2015-04-23 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
PCT/EP2016/058607 WO2016169911A1 (en) 2015-04-23 2016-04-19 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2018513180A JP2018513180A (ja) 2018-05-24
JP2018513180A5 JP2018513180A5 (https=) 2019-05-23
JP6777652B2 true JP6777652B2 (ja) 2020-10-28

Family

ID=53488521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017555303A Active JP6777652B2 (ja) 2015-04-23 2016-04-19 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物

Country Status (19)

Country Link
US (1) US10568879B2 (https=)
EP (1) EP3286191B1 (https=)
JP (1) JP6777652B2 (https=)
KR (1) KR20170139142A (https=)
CN (1) CN107531703B (https=)
AR (1) AR104362A1 (https=)
AU (1) AU2016251517A1 (https=)
BR (1) BR112017022008A2 (https=)
CA (1) CA2983342A1 (https=)
CO (1) CO2017011093A2 (https=)
GB (1) GB201506894D0 (https=)
IL (1) IL255109A0 (https=)
MX (1) MX2017013382A (https=)
PH (1) PH12017501911A1 (https=)
RU (1) RU2017134551A (https=)
SG (1) SG11201708671RA (https=)
TW (1) TW201702243A (https=)
WO (1) WO2016169911A1 (https=)
ZA (1) ZA201706674B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3403649A1 (en) * 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
CN118239937A (zh) 2017-08-09 2024-06-25 戴纳立制药公司 化合物、组合物及方法
DK3676297T3 (da) 2017-09-01 2023-08-14 Denali Therapeutics Inc Forbindelser, sammensætninger og fremgangsmåder
RU2020119415A (ru) * 2017-11-15 2021-12-16 Галапагос Нв Соединения и их фармацевтические композиции для применения при лечении фиброзных заболеваний
WO2020007342A1 (zh) * 2018-07-06 2020-01-09 中国科学院上海药物研究所 联苯磷酸酯类化合物作为gpr84拮抗剂的应用
MA54953A (fr) * 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
US12091392B2 (en) 2019-02-13 2024-09-17 Denali Therapeutics Inc. Compounds, compositions and methods
BR112022011237A2 (pt) 2019-12-19 2022-08-30 Bayer Ag Derivados de furoindazol
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
WO2022179940A1 (en) 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
EP4330260A1 (en) 2021-04-29 2024-03-06 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
EP4355743A1 (en) 2021-06-18 2024-04-24 University of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain
USD1117011S1 (en) * 2024-07-10 2026-03-10 Delta Electronics, Inc. Charging connector
USD1119767S1 (en) * 2024-07-10 2026-03-24 Delta Electronics, Inc. Charging connector

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0926148A1 (en) * 1997-12-23 1999-06-30 Applied Research Systems Ars Holding N.V. Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors
WO2005050225A2 (en) * 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
EP1929310A2 (en) 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
WO2012037782A1 (en) 2010-09-20 2012-03-29 Glaxo Group Limited Tricyclic compounds, preparation methods, and their uses
AR089284A1 (es) * 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
WO2014095798A1 (en) 2012-12-20 2014-06-26 Galapagos Nv Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
GB201411241D0 (en) * 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
SG11201708671RA (en) 2017-11-29
PH12017501911A1 (en) 2018-03-05
IL255109A0 (en) 2017-12-31
WO2016169911A1 (en) 2016-10-27
CA2983342A1 (en) 2016-10-27
MX2017013382A (es) 2017-12-07
GB201506894D0 (en) 2015-06-10
AU2016251517A1 (en) 2017-10-26
CN107531703B (zh) 2020-09-01
KR20170139142A (ko) 2017-12-18
US10568879B2 (en) 2020-02-25
JP2018513180A (ja) 2018-05-24
US20190062325A1 (en) 2019-02-28
BR112017022008A2 (pt) 2018-07-03
CO2017011093A2 (es) 2018-01-31
TW201702243A (zh) 2017-01-16
EP3286191A1 (en) 2018-02-28
AR104362A1 (es) 2017-07-12
ZA201706674B (en) 2019-07-31
EP3286191B1 (en) 2020-07-29
CN107531703A (zh) 2018-01-02
RU2017134551A (ru) 2019-04-04

Similar Documents

Publication Publication Date Title
JP6777652B2 (ja) 炎症性障害の治療のための新規ジヒドロピリドイソキノリノン及びその医薬組成物
US8937077B2 (en) Bicyclic diamines as janus kinase inhibitors
EP3692040B1 (en) Chemical compounds
JP6587116B2 (ja) キナゾリン化合物
JP6062453B2 (ja) 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物
JP6293784B2 (ja) 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物（ｇｐｒ８４アンタゴニスト）
US8759372B2 (en) N-(5S,6S,9R)-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-ctclohepta[b]Pyridin-9-yl-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-carboxylate salt
JP2021507912A (ja) ６−アザインドール化合物
JP2021527106A (ja) 新規化合物及び疾患の治療のためのその医薬組成物
KR20110137364A (ko) 축합 피롤로피리딘 유도체
JP6472454B2 (ja) 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物
JP2016505021A (ja) Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物
KR20200027543A (ko) 섬유증의 치료를 위한 신규의 화합물 및 그의 약학 조성물
WO2015197550A1 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN107106547A (zh) 作为Janus激酶抑制剂的乙基N‑Boc哌啶基吡唑并吡啶酮
JP2014507414A (ja) 代謝疾患及び炎症疾患の治療に有用なアゼチジン誘導体
TW202444385A (zh) Ｅｇｆｒ降解劑、其藥物組成物及其用途
JP2023538393A (ja) 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体
JP7573596B2 (ja) Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物
JP7751002B2 (ja) Ｐｄ－ｌ１相互作用の免疫調節剤としての複素環化合物
US20260001878A1 (en) Substituted pyrrolopyridine compounds useful as inhibitors of tlr9
US20250163054A1 (en) Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9
JP2025508426A (ja) Ｔｌｒ９の阻害剤として有用な置換イミダゾピリジニル化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200923

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201008

R150 Certificate of patent or registration of utility model

Ref document number: 6777652

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250